SCHEMBL5879303

SCHEMBL5879303

O=c1[nH]c(=O)c2c1c1[nH]c3ccc(Cl)cc3c1c1c(=O)[nH]c(=O)c21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 5/20 0.59
CYP1A2 P05177 1/20 0.51
GAA P10253 1/20 0.51
HPGD P15428 1/20 0.51
LMNA P02545 1/20 0.49
CDC25A P30304 1/20 0.48
CDC25C P30307 1/20 0.48
GRIN2D O15399 2/20 0.47
GRIN3B O60391 2/20 0.47
GRIN1 Q05586 2/20 0.47
GRIN2A Q12879 2/20 0.47
GRIN2B Q13224 2/20 0.47
GRIN2C Q14957 2/20 0.47
GRIN3A Q8TCU5 2/20 0.47
PARP1 P09874 2/20 0.46
CA12 O43570 1/20 0.45
CA9 Q16790 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6201746 0.86 CHEK1 (0.59) CHEK1HPGDLMNACDC25ACDC25C
SCHEMBL5879244 0.79 CHEK1 (0.59) CHEK1GAAHPGDLMNACDC25A
SCHEMBL5879153 0.79 CHEK1 (0.59) CHEK1PARP1CA12CA9CDK4
SCHEMBL5879181 0.79 CHEK1 (0.82) CHEK1GAAHPGDLMNAPARP1
SCHEMBL5879160 0.79 CHEK1 (0.82) CHEK1GAAMEN1KMT2AROCK2
SCHEMBL5879297 0.79 CHEK1 (0.59) CHEK1HPGDLMNAPARP1CDK2
SCHEMBL8667677 0.79 CDK2 (0.50) CHEK1CYP1A2GAAHPGDLMNA
SCHEMBL8113598 0.76 CDK4 (0.70) CHEK1PARP1MEN1KMT2ACDK2
SCHEMBL11731873 0.76 CDK2 (0.61) CHEK1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL5879238 0.76 PDGFRB (0.62) CHEK1GAAHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 CHEK1 943/4885CYP1A2 221/4885GAA 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.